Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:12:07.685Z.
Calculation as of: 2026-10-06T17:12:07.685Z.
Quote observation: 2026-10-06T17:09:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2576380beaab4b3cbce085b4235445012990db653f345db98d0cfe80ba67c11f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$52.78M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.71M
EV/Sales Ratio
158.67x
TTM Avg
123.33x
3Y Avg
165.71x
5Y Avg
999.06x
Market Cap
$50.99M
EV/Sales Ratio
10.18x
TTM Avg
51.21x
3Y Avg
45.57x
5Y Avg
60.27x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $52.46M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.78M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.83M | 0.92x | 0.87x | 1.10x | 0.92x |
| Aldeyra The (ALDX)vs › | $53.39M | N/A | 3.74x | 3.42x | 3.42x |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.71M | 158.67x | 123.33x | 165.71x | 999.06x |
| ImageneBio Inc (IMA)vs › | $53.63M | N/A | 46.89x | 17.85x | 13.82x |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $50.99M | 10.18x | 51.21x | 45.57x | 60.27x |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | 3.69x | 2.57x | 1.84x | 3.18x |
| PDS Biotechnology Corporation (PDSB)vs › | $54.16M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
